Clinical Trial

Prevalence of Hepatitis E During Follow-up Liver and Kidney Transplant Patients in Guadeloupe, French West Indies

Study acronym: KARU-HEP
Completed
View on ClinicalTrials.gov →
Summary
Hepatitis E is well known to be a common cause of severe hepatitis on organ-transplanted people. However, several studies also show a risk of transition to a chronic state. It is necessary to carry out a preliminary study in order to determine the hepatitis E prevalence in the population of the French West Indies. The aim of our study is to make a systematic screening of the hepatitis E within this risk population; hepatic and renal transplanted people. Up to now, no severe hepatitis E case was reported in the French West Indies. We would like to know if the systematic screening will change or not, this assumption.
Trial Details
NCT Number NCT07729202
Lead Sponsor Centre Hospitalier Universitaire de la Guadeloupe
Conditions Hepatitis E
Enrollment 95 participants
Start Date 2019-03-22
Primary Completion 2019-05-05 (estimated)
Study Completion 2019-05-09 (estimated)
Updated on ClinicalTrials.gov 2026-07-27